1. "GSK Faculty"
Formats
  1. Journal Article (13834)
  2. Meeting Abstract (7076)
  3. Review (514)
  4. Book Section (342)
  5. Editorial (307)
  6. Conference Paper (162)
  7. Research Letter (96)
  8. Miscellaneous (45)
  9. Correspondence (38)
  10. Guidelines (32)
  11. Book Whole (22)
Groups
  1. GSK Faculty (22468)
  2. Sloan Kettering Institute Faculty (11482)
  3. Department of Medicine (10529)
  4. Tow Center for Developmental Oncology (TCDO) (6948)
  5. Sloan Kettering Institute Postdocs (6210)
  6. Solid Tumor Oncology Division (5880)

More Groups

People
  1. Marc Ladanyi (1327)
  2. Steven Larson (957)
  3. Jedd Wolchok (905)
  4. Cristina Antonescu (895)
  5. Kenneth Offit (788)
  6. David Solit (779)

More People

Years
  1. 2025 (296)
  2. 2024 (868)
  3. 2023 (1016)
  4. 2022 (1152)
  5. 2021 (1088)
  6. 2020 (1257)

More Years

Publications
  1. Blood (1470)
  2. Journal of Clinical Oncology (1279)
  3. Cancer Research (1104)
  4. Clinical Cancer Research (527)
  5. Modern Pathology (494)
  6. Journal of Nuclear Medicine (474)

More Publications

Publishers
  1. Nature Publishing Group (2594)
  2. American Association for Cancer Research (2194)
  3. Elsevier Inc. (1937)
  4. American Society of Hematology (1553)
  5. Cell Press (1421)
  6. American Society of Clinical Oncology (1379)

More Publishers

Results (22468)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • PRMT1-mediated methylation of DUSP4 determines megakaryocyte-erythroid lineage choice by regulating p38 signaling
    Meeting Abstract

    Su, H. R.; Tran, N. T.; Guo, H.; Luo, M.; Zhao, X. T.
    Blood (2015)

    Fulltext@MSK | Save
  • Global 3' UTR sequencing in multiple myeloma (MM)
    Meeting Abstract

    Singh, I.; Samur, M. K.; Lee, S. H.; Sperling, A. S.; Tai, Y. T.; Fulciniti, M.; Leslie, C. S.; Mayr, C.; Munshi, N. C.
    Blood (2015)

    Fulltext@MSK | Save
  • RBM15-mediated RNA splicing fine-tunes epigenetic program through interaction with SF3B1
    Meeting Abstract

    Tran, N. T.; Su, H. R.; Lu, Y. H.; Leslie, C. S.; Zhao, X. Y.
    Blood (2015)

    Fulltext@MSK | Save
  • Comprehensive genomic profiling (CGP) of angioimmunoblastic T-cell lymphoma (AITL) to prospectively inform diagnosis and clinical management
    Meeting Abstract

    Morley, S.; He, J.; Intlekofer, A. M.; Bailey, M.; Nahas, M.; Lipson, D.; Yelensky, R.; Ross, J.; Ali, S.; Erlich, R.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Successful treatment of refractory CMV chorioretinitis and meningoencephalitis with adoptive transfer of third party CMVpp65 specific T-cell Lines
    Meeting Abstract

    Prockop, S.; Hasan, A.; Doubrovina, E.; Castro-Malaspina, H. R.; Barker, J. N.; Dahi, P. B.; Boulad, F.; Kernan, N. A.; Koehne, G.; Sauter, C. S.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Investigating effect of genetic admixture and donor/recipient genetic disparity on transplant outcomes
    Meeting Abstract

    Madbouly, A.; Wang, T.; Albrecht, M.; Paunic, V.; Haagenson, M. D.; Vierra-Green, C.; Fleischhauer, K.; Hsu, K. C.; Verneris, M. R.; Majhail, N. S.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • A clinical measure of DNA methylation predicts outcome in de novo AML
    Meeting Abstract

    Luskin, M. R.; Gimotty, P.; Smith, C.; Loren, A.; Figueroa, M.; Harrison, J.; Sun, Z. X.; Tallman, M. S.; Paietta, E.; Litzow, M. R.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse risk features and poor outcome in pediatric acute myeloid leukemia: A report from the Children's Oncology Group
    Meeting Abstract

    Laszlo, G. S.; Alonzo, T. A.; Gudgeon, C. J.; Harrington, K. H.; Kentsis, A.; Gerbing, R. B.; Wang, Y. C.; Ries, R. E.; Raimondi, S. C.; Hirsch, B. A.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • T-cell depleted peripheral blood stem cell (TCD-PBSC) transplants secure consistent engraftment with low risk of acute or chronic Gvhd and favorable disease free survival (DFS) and overall survival (OS) for pediatric patients (<21 years) with AML in CR1 or CR2 or MDS including tMDS/AML
    Meeting Abstract

    Kernan, N. A.; Boulad, F.; Prockop, S.; Wolden, S.; Scaradavou, A.; Kobos, R.; Lehrman, R.; Klein, E.; Curran, K. J.; Hasan, A. N.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Phase 1 trial of targeted alpha-particle immunotherapy with actinium-225 ((225)Ac)-lintuzumab (Anti-CD33) and low-dose cytarabine (LDAC) in older patients with untreated acute myeloid leukemia (AML)
    Meeting Abstract

    Jurcic, J. G.; Ravandi, F.; Pagel, J. M.; Park, J. H.; Smith, B. D.; Levy, M. Y.; Estey, E. H.; Perl, A. E.; Kantarjian, H.; Earle, D.; more...
    Blood (2015)

    Fulltext@MSK | Save